Skip to main content
. Author manuscript; available in PMC: 2021 Mar 13.
Published in final edited form as: ACS Infect Dis. 2020 Jan 15;6(3):489–502. doi: 10.1021/acsinfecdis.9b00416

Figure 4. Inhibitors of multiple levels of ARE promoter activity.

Figure 4.

(A) ARE/mVP24 HEK293T cells were distributed in a 384-well plate and treated with increasing concentrations of 5-iodotubercidin in triplicate. Twenty-four hours post-treatment firefly luciferase activity was assessed (left axis, red circles). In parallel, HEK293T cells were plated in a 384-well plate and treated in triplicate with increasing concentrations of compounds. Twenty-four hours post-treatment, ATP content was assessed to determine viability (right axis, black squares). Error bars represent the standard deviation. (B) Expression of Flag-tagged mVP24 (red circles) and endogenous Nrf2 (teal squares) expression determined relative to DMSO control for ARE/mVP24 HEK293T cells treated with 5-iodotubercidin at 5 and 1 μM for 24h. The dotted line represents the DMSO control, individual values for each of the triplicates are indicated and the error bars represent the standard deviation. (C) ARE/mVP24 HEK293T cells were treated with podophyllotoxin and analyzed as in (A). (D) Relative expression of Flag-tagged mVP24 and Nrf2 determined relative to the DMSO control. (E) ARE/mVP24 HEK293T cells were treated with the indicated compounds and analyzed, as in (A). Structures of the compounds are indicated. (F) ARE/mVP24 HEK293T cells were treated with the indicated compounds and analyzed as in (B).